Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

Journal of the American Academy of Dermatology

Volumn 71, Issue 6, 2014, Pages 1183-1190.e3

  Papp, Kim ^a   Leonardi, Craig ^b   Menter, Alan ^c   Thompson, Elizabeth H Z ^d   Milmont, Cassandra E ^d   Kricorian, Greg ^d   Nirula, Ajay ^d   Klekotka, Paul ^d  

^a PROBITY MEDICAL RESEARCH   (Canada)

^b SAINT LOUIS UNIVERSITY   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d AMGEN INC   (United States)

Author keywords

anti interleukin 17 therapy; brodalumab; clinical trial; efficacy; long term treatment; open label extension; psoriasis; safety

Indexed keywords

BRODALUMAB; PLACEBO; DERMATOLOGICAL AGENT; INTERLEUKIN 17 RECEPTOR; MONOCLONAL ANTIBODY;

ABSCESS; ACUTE CHOLECYSTITIS; ACUTE PYELONEPHRITIS; ADULT; AORTA RUPTURE; ARTHRALGIA; ARTICLE; ATRIAL FIBRILLATION; BACKACHE; BILE DUCT STONE; BRONCHITIS; CHOLECYSTITIS; CLINICAL PROTOCOL; CONSTIPATION; DERMATOLOGY LIFE QUALITY INDEX; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEMALE; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HEART FAILURE; HUMAN; HYPERTENSION; INFLUENZA; INTERVERTEBRAL DISK HERNIA; LIMB PAIN; LUMBAR SPINAL STENOSIS; MAJOR CLINICAL STUDY; MALE; MUSCLE STRAIN; NECROTIZING FASCIITIS; NEPHROLITHIASIS; NEUTROPHIL COUNT; OPEN STUDY; OROPHARYNX PAIN; OSTEOARTHRITIS; PARATHYROID TUMOR; PHASE 2 CLINICAL TRIAL; PHYSICIAN; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; PYELONEPHRITIS; QUALITY OF LIFE; RHINOPHARYNGITIS; SEPTIC SHOCK; SINUSITIS; SKIN TOXICITY; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION; VIRUS MENINGITIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL (TOPIC); DOSE RESPONSE; IMMUNOLOGY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; CONTROLLED CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, INTERLEUKIN-17; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84925226246     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.08.039     Document Type: Article

References (15)

1. C.G. Helmick, H. Lee-Han, S.C. Hirsch, T.L. Baird, and C.L. Bartlett Prevalence of psoriasis among adults in the US: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys Am J Prev Med 47 2014 37 45
2. T.D. Rachakonda, C.W. Schupp, and A.W. Armstrong Psoriasis prevalence among adults in the United States J Am Acad Dermatol 70 2014 512 516
3. E.A. Dowlatshahi, M. Wakkee, L.R. Arends, and T. Nijsten The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis J Invest Dermatol 134 2014 1542 1551
4. H. Yeung, J. Takeshita, N.N. Mehta, S.E. Kimmel, A. Ogdie, and D.J. Margolis Psoriasis severity and the prevalence of major medical comorbidity: a population-based study JAMA Dermatol 149 2013 1173 1179
5. T.J. Love, A.A. Qureshi, E.W. Karlson, J.M. Gelfand, and H.K. Choi Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006 Arch Dermatol 147 2011 419 424
6. C. Han, J.H. Lofland, N. Zhao, and B. Schenkel Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis J Drugs Dermatol 10 2011 843 850
7. M. Makredes, D. Robinson Jr., M. Bala, and A.B. Kimball The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis J Am Acad Dermatol 61 2009 405 410
8. C. Ryan, N.J. Korman, J.M. Gelfand, H.W. Lim, C.A. Elmets, and S.R. Feldman Research gaps in psoriasis: opportunities for future studies J Am Acad Dermatol 70 2014 146 167
9. M.A. Lowes, T. Kikuchi, J. Fuentes-Duculan, I. Cardinale, L.C. Zaba, and A.S. Haider Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells J Invest Dermatol 128 2008 1207 1211
10. C. Johansen, P.A. Usher, R.B. Kjellerup, D. Lundsgaard, L. Iversen, and K. Kragballe Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin Br J Dermatol 160 2009 319 324
11. E.G. Harper, C. Guo, H. Rizzo, J.V. Lillis, S.E. Kurtz, and I. Skorcheva Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis J Invest Dermatol 129 2009 2175 2183
12. C. Russell, K. Kerkof, J. Bigler, M. Timour, A. Welcher, and E. Bautista Blockade of the IL-17R with AMG 827 leads to rapid reversal of gene expression and histopathologic abnormalities in psoriatic skin, including substantial pathway-specific effects within one week [abstract 065] J Invest Dermatol 131 2011 S11
13. C. Russell, K. Kerkof, J. Bigler, M. Timour, A. Welcher, and I. Novitskaya Blockade of the IL-17R with AMG 827 leads to rapid reversal of gene expression and histopathologic abnormalities in human psoriatic skin [abstract 273] J Invest Dermatol 130 2010 S46
14. K.A. Papp, C. Leonardi, A. Menter, J.P. Ortonne, J.G. Krueger, and G. Kricorian Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis N Engl J Med 366 2012 1181 1189
15. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Available from: URL: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf. Accessed August 19, 2014.